CYBN News & Events

Cybin announced that the company will operate under the business name Helus Pharma and trade on Nasdaq with ticker symbol (HELP). The company has transferred its U.S. stock exchange listing from the NYSE American to the Nasdaq. The company will continue to be listed on the Cboe Canada and will trade under the same ticker symbol. The company expects to seek approval from shareholders to change its legal name to Helus Pharma at the company's next annual and special meeting of shareholders.

Cybin announced that it has launched an at-the-market equity program to allow Cybin to issue and sell up to $100M of common shares in the capital of the company from treasury to the public, from time to time, through Cantor Fitzgerald and Co. and Cantor Fitzgerald Canada Corporation.

Jefferies analyst Andrew Tsai notes that the highest level of the U.S. government has signed an executive order to encourage the DEA to reschedule medical marijuana to a less stringent CIII for CNS indications like pain. The firm could see non-recreational psychedelics eventually follow suit, as long as sponsors continue producing Phase II/III data to suggest psychedelics can safely produce profound efficacy in mental health - arguably a function of time. Jefferies notes it thinks Atai Beckley's (ATAI) proprietary psychedelics have promise in tough $1B-plus mental health disorders. Other publicly traded companies in the space include Supernus (SUPN) and Cybin (CYBN).